Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 62 clinical trials
Featured trial
TAKEDA EXAMINE trial patients for who have Type II diabetes & ACS coronary artery disease, post angiogram or heart attack. This is a phase 3b study. Currently open for enrollment.

TAKEDA EXAMINE trial patients for who have Type II diabetes & ACS coronary artery disease, post angiogram or heart attack. This is a phase 3b study. Currently open for enrollment.

  • 303 views
  • 08 Nov, 2020
  • 1 location
Glucagon-like Peptide-1 in Type 1 Diabetes

The hypotheses to be tested in this application is: GLP-1 will acutely protect arterial endothelial function and reduce pro-atherothrombotic and pro-coagulant effects of repeated hypoglycemia in T1DM.

  • 0 views
  • 27 Apr, 2022
  • 1 location
[68Ga]Ga-HBED-CC-exendin-4 and [68Ga]Ga-NOTA-exendin-4 PET/CT Imaging in the Same Group of Insulinoma Patients

Glucagon-like peptide-1 receptor (GLP-1R)-targeted PET imaging with 68Ga-labeled compounds is able to provide superior sensitivity and specificity to detect insulinoma, like the widely studied

  • 1 views
  • 12 Sep, 2021
  • 1 location
Semaglutide in Comorbid Schizophrenia Spectrum Disorder and Obesity (Sema)

approved for chronic weight management, glucagon-like peptide-1 receptor agonists (GLP-1RA) are associated with reductions in cardiovascular mortality, with recent FDA approval for once weekly semaglutide

  • 0 views
  • 08 Jul, 2022
  • 1 location
GLP-1 Analogue in Preventing Progression of Small Vessel Disease (GAPP-SVD) (GAPP-SVD)

be sufficient to prevent the development of vascular cognitive impairment (VCI) in patients with cSVD according to previous clinical trials. The presence of glucagon-like peptide-1 receptor

  • 0 views
  • 27 Jul, 2022
  • 1 location
INSULIN THERAPY DE-INTENSIFICATION WITH iGlarLixi

(FRC) of a basal insulin and a glucagon-like peptide-1 receptor agonist (GLP-1 RA), which can offer similar efficacy in glucose control with lower rates of hypoglycemia and smaller weight gain that

  • 0 views
  • 31 Jul, 2021
  • 1 location
Lifestyle Counseling and Medication for Adolescent Weight Management (QUEST)

The prevalence of adolescent severe obesity is at an all-time high in the United States and the refractory nature of this disease has led to a serious and challenging conundrum in terms of how to provide effective, safe, scalable, and durable treatments without placing undue strain on the healthcare system. …

  • 0 views
  • 17 Mar, 2022
  • 1 location
The Clinical Application of 68Ga-NOTA-exendin-4 PET/CT in Detecting Insulinoma

The small insulinoma can not be detected by the CT or MRI. We use 68Ga-NOTA-exendin-4 positron emission tomography/computed tomography (PET/CT) to detect the insulinoma for the patient diagnosed with endogenous hyperinsulinemic hypoglycaemia. And the diagnostic value will be performed. A single dose of 37-111 Mega-Becquerel (MBq) 68Ga-NOTA-exendin-4 will be injected …

  • 0 views
  • 08 Aug, 2021
  • 1 location
Effect of Gender Affirming Hormone Therapy on Glucose Metabolism

The study will test: whether estrogen treatment in transwomen is associated with improved insulin sensitivity and beta cell function whether testosterone treatment in transmen is associated with worsening insulin sensitivity and beta cell function whether estrogen therapy leads to enhanced immune response in older transwormen

Accepts healthy volunteers
  • 24 views
  • 23 Mar, 2022
  • 1 location
Metabolic Phenotyping During Stress Hyperglycemia in Cardiac Surgery Patients

The study is a prospective randomized study to examine the effects of exposure to dulaglutide on the prevention of stress-hyperglycemia and the metabolic inflammatory response in the perioperative period

  • 0 views
  • 02 Aug, 2021
  • 3 locations